{"id":"https://openalex.org/W2516969293","doi":null,"title":"Serum glucose measurements as a pharmacodynamic biomarker for mTOR inhibition","display_name":"Serum glucose measurements as a pharmacodynamic biomarker for mTOR inhibition","publication_year":2007,"publication_date":"2007-11-01","ids":{"openalex":"https://openalex.org/W2516969293","mag":"2516969293"},"language":"en","primary_location":{"id":"mag:2516969293","doi":null,"is_oa":false,"landing_page_url":"http://mct.aacrjournals.org/content/6/11_Supplement/C292","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5039768907","display_name":"Laura Sit","orcid":"https://orcid.org/0000-0002-4950-1434","observed_orcids":["https://orcid.org/0000-0002-4950-1434"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura Sit","raw_affiliation_strings":["University of Chicago, Chicago, IL;"],"raw_orcid":"https://orcid.org/0000-0002-4950-1434","affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL;","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066578904","display_name":"Kristen Kasza","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristen Kasza","raw_affiliation_strings":["University of Chicago, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL;","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039500951","display_name":"Theodore Karrison","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Theodore Karrison","raw_affiliation_strings":["University of Chicago, Chicago, IL;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL;","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005159945","display_name":"Sonali M. Smith","orcid":"https://orcid.org/0000-0002-9893-4949","observed_orcids":["https://orcid.org/0000-0002-9893-4949"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sonali M. Smith","raw_affiliation_strings":["University of Chicago, Chicago, IL;"],"raw_orcid":"https://orcid.org/0000-0002-9893-4949","affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL;","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001334189","display_name":"Ezra E.W. Cohen","orcid":"https://orcid.org/0000-0002-9872-6242","observed_orcids":["https://orcid.org/0000-0002-9872-6242"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ezra E.W. Cohen","raw_affiliation_strings":["University of Chicago, Chicago, IL;"],"raw_orcid":"https://orcid.org/0000-0002-9872-6242","affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL;","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068268371","display_name":"Mark J. Ratain","orcid":"https://orcid.org/0000-0002-0938-4392","observed_orcids":["https://orcid.org/0000-0002-0938-4392"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark J. Ratain","raw_affiliation_strings":["University of Chicago, Chicago, IL;"],"raw_orcid":"https://orcid.org/0000-0002-0938-4392","affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL;","institution_ids":["https://openalex.org/I40347166"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036578095","display_name":"Michael L. Maitland","orcid":"https://orcid.org/0000-0002-2476-5732","observed_orcids":["https://orcid.org/0000-0002-2476-5732"]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael L. Maitland","raw_affiliation_strings":["University of Chicago, Chicago, IL;"],"raw_orcid":"https://orcid.org/0000-0002-2476-5732","affiliations":[{"raw_affiliation_string":"University of Chicago, Chicago, IL;","institution_ids":["https://openalex.org/I40347166"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I40347166"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.28035503,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"6","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9657999873161316,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9657999873161316,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11314","display_name":"Clinical Laboratory Practices and Quality Control","score":0.005100000184029341,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.004399999976158142,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/serum-glucose","display_name":"serum glucose","score":0.8140000104904175},{"id":"https://openalex.org/keywords/mtor-inhibition","display_name":"mTOR inhibition","score":0.7900000214576721},{"id":"https://openalex.org/keywords/pharmacodynamic-markers","display_name":"pharmacodynamic biomarkers","score":0.9700000286102295},{"id":"https://openalex.org/keywords/rapamycin","display_name":"rapamycin","score":0.9470000267028809},{"id":"https://openalex.org/keywords/temsirolimus","display_name":"temsirolimus","score":1.0},{"id":"https://openalex.org/keywords/hyperglycemia","display_name":"hyperglycemia","score":0.9409999847412109},{"id":"https://openalex.org/keywords/fasting-blood-glucose","display_name":"fasting blood glucose","score":0.5130000114440918},{"id":"https://openalex.org/keywords/measurement-variability","display_name":"measurement variability","score":0.6330000162124634},{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.6919999718666077},{"id":"https://openalex.org/keywords/drug-exposure-monitoring","display_name":"drug exposure monitoring","score":0.550000011920929},{"id":"https://openalex.org/keywords/cancer-treatment-side-effects","display_name":"cancer treatment side effects","score":0.46399998664855957},{"id":"https://openalex.org/keywords/immunosuppression","display_name":"immunosuppression","score":0.39899998903274536},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.44999998807907104}],"concepts":[{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.6288707256317139},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6233181953430176},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5663012862205505},{"id":"https://openalex.org/C2776820818","wikidata":"https://www.wikidata.org/wiki/Q7699074","display_name":"Temsirolimus","level":5,"score":0.5355413556098938},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5326069593429565},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.4646330177783966},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4563501477241516},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.27715325355529785},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.1900065541267395},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.18260368704795837},{"id":"https://openalex.org/C183713625","wikidata":"https://www.wikidata.org/wiki/Q5282002","display_name":"Discovery and development of mTOR inhibitors","level":4,"score":0.11540910601615906},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.06417229771614075},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2516969293","doi":null,"is_oa":false,"landing_page_url":"http://mct.aacrjournals.org/content/6/11_Supplement/C292","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.75}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2341604011","https://openalex.org/W1731221805","https://openalex.org/W2156145961","https://openalex.org/W582601826","https://openalex.org/W2044793090","https://openalex.org/W2571201658","https://openalex.org/W1850282902","https://openalex.org/W2055269100","https://openalex.org/W6950405985","https://openalex.org/W2032195526"],"abstract_inverted_index":{"C292":[0],"Hyperglycemia":[2],"is":[3,118,296],"a":[4,24,37,128,156,279,292,319],"mechanism-based":[5,280],"toxicity":[6],"of":[7,9,13,57,65,88,131,217,282,294,328],"inhibitors":[8],"the":[10,114,286,325],"mammalian":[11],"target":[12],"rapamycin":[14],"(mTOR)":[15],"and":[16,139,207,213,264,285,310],"change":[17,32,97,140,242,266],"in":[18,33,141,324],"serum":[19,34,39,73,83,159,316],"glucose":[20,35,40,74,84,121,134,137,142,173,176,209,226,234,252,261,276,305,317],"could":[21],"therefore":[22],"be":[23,312],"pharmacodynamic":[25],"biomarker":[26,320,330],"for":[27,50,63,109,152,163,185,247,321],"these":[28,123,147],"drugs.":[29],"To":[30],"develop":[31,315],"as":[36,155,278,318],"biomarker,":[38,157],"measurements":[41,174,210,249,306],"from":[42],"70":[43],"patients":[44,295],"who":[45],"received":[46],"mTOR":[47,66,116,218,283,322],"inhibitor":[48,219],"therapy":[49,89],"at":[51,211],"least":[52],"35":[53,268],"days":[54],"on":[55],"trials":[56],"sirolimus":[58],"or":[59],"temsirolimus":[60],"were":[61,161],"examined":[62],"effects":[64],"exposure.":[67],"For":[68,167,221],"all":[69,201],"subjects,":[70,202],"mean":[71,82,96,175,192,224,232,241,250,259,265],"pre-treatment":[72,133,172,190,212,225,251],"was":[75,90],"100mg/dl":[76],"[standard":[77],"deviation":[78],"(SD)":[79],"=":[80,93,100,107,177,180,183,193,227,235,239,243,253,257,262,267],"22],":[81],"after":[85,214],"4":[86,215],"weeks":[87,216],"111mg/dl":[91],"[SD":[92,99,179,230,238,256,269],"31],":[94],"with":[95,120,170,188,275],"+11mg/dl":[98],"33,":[101],"95%":[102],"C.I.":[103],"(+3,":[104],"+18),":[105],"p":[106],"0.0049":[108],"paired":[110],"t-test].":[111],"Although":[112],"across":[113],"population":[115,288],"inhibition":[117,284,323],"associated":[119],"elevation,":[122],"unstructured":[124],"specimen":[125],"collections":[126],"had":[127,204],"broad":[129,151,287],"range":[130,182],"values:":[132],"[42-177mg/dl],":[135],"on-treatment":[136,233,260],"[43-214mg/dl],":[138],"[-82":[143],"-":[144],"+121mg/dl].":[145],"As":[146],"ranges":[148],"are":[149,273],"too":[150],"reproducible":[153],"use":[154],"fasting":[158,189,206,248],"measures":[160,191],"evaluated":[162],"reduced":[164],"measurement":[165,308],"variability.":[166],"22":[168],"subjects":[169,187],"non-fasting":[171,208,222],"107mg/dl":[178],"25;":[181],"66-177mg/dl],":[184],"48":[186],"97mg/dl":[194],"[SD=":[195],"20;":[196],"range=":[197],"42-169":[198],"mg/dl].":[199],"Of":[200],"12":[203],"both":[205],"therapy.":[220],"measurements:":[223],"109.5":[228],"mg/dl":[229,237,255],"=35],":[231],"128.2":[236],"53],":[240],"19":[244],"[SD=54]":[245],"while":[246],"87.5":[254],"21],":[258],"122.3,":[263],"=43].":[270],"These":[271],"data":[272],"consistent":[274],"elevation":[277],"effect":[281,300],"distribution":[289],"suggests":[290],"that":[291],"subset":[293],"susceptible":[297],"to":[298,314],"this":[299],"more":[301],"than":[302],"others.":[303],"Fasting":[304],"reduce":[307],"variability":[309],"will":[311],"used":[313],"next":[326],"phase":[327],"clinical":[329],"studies.":[331]},"counts_by_year":[],"updated_date":"2025-10-10T17:16:08.811792","created_date":"2016-09-16T00:00:00"}